Innovator risks over generic warnings

Share this article:

Responding to a federal court question, the Alabama Supreme Court ruled that a man who claims he was injured by a generic version of Pfizer's Reglan can sue the innovator company for not properly warning his doctor about the drug's risks.

The court said that in the context of inadequate warnings by the brand-name manufacturer put on a prescription drug manufactured by a generic company, it is “not fundamentally unfair to hold the brand-name manufacturer liable for warnings on a product it did not produce.”

An attorney for the patient told media outlets that the “learned intermediary” doctrine applies in this case since under Alabama law companies are to inform doctors about drug risks and the presumption is that if a warning is adequate, then the doctor has warned the patient.

Pfizer told the media that the ruling applies only to Alabama and does not reflect the case's merits or the fact that four federal appeals courts have held that innovator companies aren't liable for injuries to consumers who took generic Reglan.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?